Guggenheim Cuts Nanobiotix (NASDAQ:NBTX) Price Target to $8.00

Nanobiotix (NASDAQ:NBTX) had its target price reduced by Guggenheim from $12.00 to $8.00 in a report issued on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Trading Down 3.3 %

NASDAQ:NBTX opened at $3.27 on Friday. The stock has a 50-day simple moving average of $3.59 and a 200 day simple moving average of $3.78. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $7.51.

Hedge Funds Weigh In On Nanobiotix

A number of large investors have recently modified their holdings of NBTX. Geode Capital Management LLC bought a new stake in Nanobiotix during the fourth quarter worth about $29,000. Millennium Management LLC acquired a new position in shares of Nanobiotix during the 4th quarter worth approximately $39,000. Jane Street Group LLC bought a new stake in shares of Nanobiotix during the 4th quarter worth approximately $73,000. Finally, OLD Mission Capital LLC acquired a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $139,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.